Medical Developments International Builds Penthrox Momentum on Improved Cash Flow

Medical Developments International (ASX: MVP) lifted revenue 9% to $42.6 million in FY26 as stronger Penthrox demand helped offset softer sales from its Respiratory segment.

Free cash flow improved by $5.8m to $4.2m, while the group closed 30 June with $21.4m in cash and short-term deposits.

Net profit after tax rose to $0.6m from $0.1m and EBIT improved to a $0.2m profit from a $48,000 loss.

Growth centred on Penthrox, with Australian hospital volumes up 28% and European in-market demand increasing 18% as the paediatric indication was approved and launched across the UK and European markets.

Broader Penthrox Demand

Pain Management revenue increased to $31.6m from $26.2m and segment EBIT climbed 49% to $9.4m, supported by higher Penthrox volumes, improved Australian pricing, and partner inventory movements.

Australian Penthrox revenue rose 16% to $17.9m as overall volume increased 9%, hospital demand grew 28% and average selling prices improved 7%.

European revenue reached $9.0m as in-market demand grew 18%, although lower transfer prices following the transition to partner supply in France and Switzerland reduced revenue by about $1.4m.

Rest of World revenue increased to $4.1m, including a $1.1m timing benefit from changes in partner stock holdings, while the broader Pain Management result included about $2m of inventory timing benefits.

“We have delivered a solid financial performance in FY26 with strong cash flow generation,” chief executive officer Brent MacGregor said.

Balance Sheet Strength

Operating cash flow improved to $5.8m from about breakeven as stronger cash earnings combined with a $5.2m year-on-year reduction in working capital used and lower capital expenditure.

Capital expenditure eased to $0.8m following completion of the MAGPIE paediatric study in the prior period, with expenditure of about $1.5m expected in FY27.

Respiratory revenue fell 15% to $10.9m amid softer demand in Australia and the US, although segment EBIT increased 63% to $0.7m following higher US pricing, reduced commercial investment and a refund of tariffs paid for FY25 and FY26.

Group earnings also absorbed a $0.9m loss from exchange rate changes on monetary items compared with a $1.6m gain in the prior year, alongside higher medical and commercial spending intended to accelerate Penthrox penetration.

Paediatric Approval Support

Penthrox can now be used by children aged six years and older in the UK and European markets after the approved indication was broadened from adults, expanding the eligible patient population.

The MAGPIE paediatric study was published during FY26, while separate health economic research found that use of Penthrox in hospital emergency departments can deliver whole-of-department cost and operational savings compared with standard care.

Medical Developments also expanded access in Australia after Nurse Practitioners were added to Pharmaceutical Benefits Scheme Prescriber Bag criteria for Penthrox in October 2025.

For FY27, the group expects higher in-market Penthrox demand supported by the paediatric indication and health economic data, stable Respiratory demand and no repeat of FY26 inventory stocking benefits.

About $1m of amortisation relating to capitalised European paediatric registration costs is expected in FY27, while the earnings impact of Middle East supply chain disruption and US tariffs remains uncertain and is being monitored.